CXCR3

AIM ImmunoTech Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen® for the Treatment of Advanced Recurrent Ovarian Cancer

Retrieved on: 
Wednesday, November 8, 2023
MSD, Society for Immunotherapy of Cancer, Plasma, AIM, NYSE, Ovarian cancer, Biomarker, Therapy, Tumor necrosis factor, Viral, TNF, Pembrolizumab, DSM-IV codes, Cisplatin, PBMC, CXCL9, Research, CXCR3, University of Pittsburgh School of Medicine, Function (mathematics), SITC, Immunotherapy, CXCL11, Perforin-1, Cancer, Annual general meeting, University, Tumor microenvironment, CXCL10, Wilfrid Sellars, TME, IP, Patient, UPMC, Pharmaceutical industry, Merck

OCALA, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, today announced encouraging translational data from an ongoing Phase 2 clinical trial utilizing AIM’s drug Ampligen® in patients with platinum-sensitive advanced recurrent ovarian cancer.

Key Points: 
  • The data was also made available at the conference in a poster presentation .
  • Sequential sampling of the IP cavity showed an increase in cellularity immediately after treatment consistent with an “acute” pro-inflammatory reaction.
  • These data show a similar profile to previously published data from Roswell Park in Stage 4 triple negative breast cancer.
  • Additionally, we hope to announce topline interim survival results from UPMC in the near future.”
    For more information about the Phase 2 clinical trial of platinum-sensitive advanced recurrent ovarian cancer utilizing Ampligen®, visit clinicaltrials.gov and reference identifier: NCT03734692.

KaliVir Immunotherapeutics Announces New In Vivo Data Demonstrating Superior Therapeutic Efficacy of VET3-TGI at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Retrieved on: 
Friday, May 19, 2023
Gene, TGF, CSO, Neoplasm, Toxicity, Doctor of Philosophy, CXCR3, Immunosuppression, TME, Annual general meeting, Cell, Virus, Tumor microenvironment, Society, Pharmaceutical industry, Vaccine

PITTSBURGH, May 19, 2023 /PRNewswire/ -- KaliVir Immunotherapeutics, Inc. , a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announced the presentation of new data on its lead pre-clinical candidate VET3-TGI at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting.

Key Points: 
  • PITTSBURGH, May 19, 2023 /PRNewswire/ -- KaliVir Immunotherapeutics, Inc. , a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announced the presentation of new data on its lead pre-clinical candidate VET3-TGI at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting.
  • The functionality and therapeutic activity of VET3-TGI were tested in multiple models, and the mechanism of action and toxicity profile were assessed.
  • Compared to control virus-treated mice, VET3-TGI showed improved delivery to tumors following systemic administration, as well as reduced systemic toxicity.
  • Novel Oncolytic therapy VET3-TGI restricts TGFβ1 and augments Type-1 immune response in TME, leading to superior therapeutic efficacy in multiple preclinical tumor models.

KaliVir Immunotherapeutics Announces Presentation at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Retrieved on: 
Wednesday, May 3, 2023
CXCR3, Annual general meeting, Neoplasm, Gene, TGF, Virus, Society, Cell, TME, Vaccine

PITTSBURGH, May 3, 2023 /PRNewswire/ -- KaliVir Immunotherapeutics, Inc. , a biotech company developing cutting-edge, multi-therapeutic oncolytic viral immunotherapy programs, today announced that its Director of Immunology, Ravikumar Muthuswamy, Ph.D., will present "Novel Oncolytic therapy VET3-TGI restricts TGFβ1 and augments Type-1 immune response in TME, leading to superior therapeutic efficacy in multiple preclinical tumor models," an overview of data on its lead pre-clinical candidate, VET3-TGI, in an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting.

Key Points: 
  • PITTSBURGH, May 3, 2023 /PRNewswire/ -- KaliVir Immunotherapeutics, Inc. , a biotech company developing cutting-edge, multi-therapeutic oncolytic viral immunotherapy programs, today announced that its Director of Immunology, Ravikumar Muthuswamy, Ph.D., will present "Novel Oncolytic therapy VET3-TGI restricts TGFβ1 and augments Type-1 immune response in TME, leading to superior therapeutic efficacy in multiple preclinical tumor models," an overview of data on its lead pre-clinical candidate, VET3-TGI, in an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting.
  • The presentation is on Friday, May 19, 2023 at 5:15 PM PST.
  • VET3-TGI is based on KaliVir's unique Vaccinia Enhanced Template (VET™) platform, capable of generating potent novel oncolytic vaccinia viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread.
  • VET3-TGI incorporates modifications granting the expression of CXCR3, IL-12 and a TGF-β inhibitor, allowing for efficient trafficking to the tumor, activation of anti-tumor immune responses and inhibition of immunosuppressive activity.

KaliVir Appoints Industry Veteran Adina Pelusio as Senior Vice President of Clinical Operations to Lead Clinical Development Pipeline

Retrieved on: 
Tuesday, November 1, 2022
Astellas Pharma, Dove Medical Press, Growth, CEO, Jennerex, Leadership, Cancer, Virus, Research, Pelusios, SillaJen, Roche, University, Public health, Neoplasm, Vaccinia, VET, CXCR3, Patient, Senior, Drug development, Potyvirus, Therapy, Harvard University, Tumor microenvironment, Pharmaceutical industry, Vaccine

PITTSBURGH, Nov. 1, 2022 /PRNewswire/ -- KaliVir Immunotherapeutics, Inc. , a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announced the appointment of Adina Pelusio, M.S., as Senior Vice President of Clinical Operations.

Key Points: 
  • PITTSBURGH, Nov. 1, 2022 /PRNewswire/ -- KaliVir Immunotherapeutics, Inc. , a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announced the appointment of Adina Pelusio, M.S., as Senior Vice President of Clinical Operations.
  • Pelusio will be responsible for leading KaliVir's clinical development program and clinical operations.
  • "Adina is an industry veteran with experience in all facets of clinical development, and her leadership will be instrumental as we advance our pipeline of novel oncolytic therapies toward the clinic, including our lead candidate VET3-TGI."
  • She most recently served as Senior Vice President of Clinical Operations at Turnstone Biologics, where she oversaw the advancement of candidate oncolytic viruses, cancer vaccines and adoptive cell therapies into clinical trials.

KaliVir Immunotherapeutics to Present Data on its Novel Pre-Clinical Oncolytic Therapy VET3-TGI at the Society for Immunology of Cancer (SITC) Annual Meeting

Retrieved on: 
Wednesday, October 5, 2022
Immunology, Therapy, Vaccinia, Neoplasm, Virus, SITC, Roche, Patient, Cancer, Convention center, Tumor microenvironment, CXCR3, Society, Astellas Pharma, MA, VET, Vaccine

Location: Poster Hall, Boston Convention and Exhibition Center, Boston, MA

Key Points: 
  • Location: Poster Hall, Boston Convention and Exhibition Center, Boston, MA
    KaliVir Immunotherapeutics is a privately held biotech company developing cutting-edge, multi-therapeutic oncolytic viral immunotherapy programs.
  • KaliVir's oncolytic virus candidates are designed to be safe, potent and systemically deliverable to treat cancer patients across multiple tumor types.
  • KaliVir has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic vaccinia viruses derived from the VET platform.
  • In addition, Astellas entered into a world-wide exclusive license to develop and commercialize KaliVir's initial lead clinical candidate VET2-L2 oncolytic vaccinia virus.

Second Genome Appoints Joseph Dal Porto, Ph.D., as Chief Scientific Officer

Retrieved on: 
Wednesday, January 19, 2022
Biomarker, Research, Technology, Center, Biotechnology, Genome, Inflammatory bowel disease, Innovation, Gastroenterology, CD20, Extrapyramidal system, Johns Hopkins University, Science, Gilead Sciences, Autoimmune disease, Biomedicine, Disease, Roche, Rituximab, Arena Pharmaceuticals, Modus, Industry, Maryland School, University of Maryland School of Medicine, CRISPR, Second Genome, CXCR3, Drug development, Therapy, Data science, IBD, Cancer, Immunology, CTI, Gilead, Drug discovery, University, Pharmaceutical industry, Pfizer, Microbiology, Biochemistry

BRISBANE, Calif., Jan. 19, 2022 /PRNewswire/ -- Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers from public and proprietary microbiome data, today announced the appointment of Joseph Dal Porto, Ph.D., as Chief Scientific Officer.

Key Points: 
  • BRISBANE, Calif., Jan. 19, 2022 /PRNewswire/ -- Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers from public and proprietary microbiome data, today announced the appointment of Joseph Dal Porto, Ph.D., as Chief Scientific Officer.
  • He has been extensively involved in the development of small and large molecule medicines, guiding their advancement into the clinical and commercial stages.
  • "Joe holds an impressive depth of expertise and track record leading the discovery and development of novel therapeutics and biomarkers," said Karim Dabbagh, Ph.D., President and Chief Executive Officer of Second Genome.
  • At CTI, Dr. Dal Porto directed the application of biopharmaceutical know-how and technology to bring ground-breaking scientific innovations to the clinic in multiple therapeutic areas.

Second Genome Presents Preclinical Data at SITC 2021 Demonstrating that a CXCR3-Positive Allosteric Modulator, SG-3-00802, Targets a Key Mechanism Required for Efficacious Immunotherapy

Retrieved on: 
Friday, November 12, 2021
D.C, SITC, Immunity, Drug development, IBD, Cancer, Arena Pharmaceuticals, Biomarker, Industry, Genome, CXCR3, Cytokine, Gilead, Gilead Sciences, Immune system, Gastroenterology, Cancer immunotherapy, Society, Tumor microenvironment, Program, Second Genome, Inflammatory bowel disease, Biotechnology, Annual general meeting, Company, Therapy, Data science, Society for Immunotherapy of Cancer, Immunotherapy, CRISPR, IND, Vaccine, Pharmaceutical industry

The data (E-Poster #569) were presented at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting, held virtually and in Washington, D.C. November 10-14.

Key Points: 
  • The data (E-Poster #569) were presented at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting, held virtually and in Washington, D.C. November 10-14.
  • "At SITC, we presented new data showing SG-3-00802 potently enhances CXCR3 ligand-induced cell migration, a critical effector cell recruitment mechanism for anti-tumor immunity.
  • We look forward to further advancing our program with an IND submission expected in 2022."
  • We also collaborate with industry, academic and governmental partners to leverage our microbiome platform and data science.